Lauxera Capital Partners, with offices in Paris and San Francisco, has completed fundraising for its second Healthtech growth fund, surpassing €400 million and reaching its target in record time. Named Lauxera Growth II, the fund embodies the firm’s mission to turn Europe’s healthtech pioneers into global market leaders by offering a hands-on, operational approach that distinguishes Lauxera from traditional investors.
Founded in 2020, Lauxera was established by Samuel Levy, a physician-turned-entrepreneur; Pierre Moustial, a seasoned pharmaceutical executive with CEO experience; and Alex Slack, a healthcare investment specialist. Together, they bring a blend of medical insight, industry leadership, and investment expertise rooted in both European and American markets.
Pierre Moustial, Lauxera’s Co-Founding Partner, says, “This rapid fundraising, despite tight market conditions, shows the strong confidence of our investors in our vision. We want to build bridges across the Atlantic to help strong, useful Healthtech solutions emerge and scale. Our transatlantic presence and diverse team give us the means to accelerate their growth, especially in the American market.”
Lauxera Growth II has already made key investments, including a €50 million stake in Germany’s Acandis. Acandis develops cutting-edge neurovascular devices for stroke and aneurysm treatment, and has established a manufacturing footprint across more than 60 countries. Another significant investment is in Sweden’s Antaros Medical, which uses AI-powered imaging technologies to improve the efficiency of clinical trials in fields such as obesity and immunology.
Unlike many European funds that enter earlier or take a more hands-off approach, Lauxera prides itself on its operational support. The team helps portfolio companies navigate complex U.S. regulations, scale commercial operations, and expand internationally. This approach proved successful with Lauxera Growth I’s portfolio company OrganOx, which was acquired by Japan’s Terumo group in August 2025 for $1.5 billion.
With a thorough review process analysing over 1,000 opportunities each year and a track record including companies like Natural Cycles, the only FDA-approved non-hormonal contraception app, Lauxera’s model is resonating with investors and founders alike, eager to scale beyond Europe’s fragmented markets.
Looking forward, the fund remains open for new investors and plans to announce a third significant investment shortly. Lauxera is focusing on sectors ripe for industrial-scale innovation, including AI-driven diagnostics, smart medical devices, and platforms enhancing healthcare delivery.
